What Happened
Eli Lilly reported topline results on Wednesday from TRANSCEND-T2D-2, the first Phase 3 trial to pit its investigational triple agonist retatrutide against another incretin medicine — Novo Nordisk's Ozempic (semaglutide) 2 mg, the highest approved dose of that drug.
The trial randomized 1,298 adults with type 2 diabetes inadequately controlled on metformin, with or without an SGLT2 inhibitor. Participants began with an average A1C of 8.3% and an average weight of 225.8 lb (BMI 36.8), and were assigned 2:2:1 to retatrutide 9 mg, retatrutide 12 mg, or Ozempic 2 mg, once weekly for 80 weeks.
On the primary endpoint, the 12 mg arm met its noninferiority objective and then some: A1C fell by an average of 2.2 percentage points versus 1.8 points with Ozempic, a statistically significant difference. The 9 mg arm also averaged 2.2 points, though Lilly described that comparison as nominally significant rather than fully controlled for multiple testing.
The weight gap was wider. Participants on retatrutide 9 mg lost an average of 44.3 lb (19.5%) and those on 12 mg lost 47.4 lb (20.9%), against 20.9 lb (9.4%) on Ozempic — more than double at the higher dose. Lilly also reported greater improvements in non-HDL cholesterol, triglycerides, and systolic blood pressure.
Tolerability cut the other way. Gastrointestinal events were common in all arms, but dysesthesia — an unusual skin sensation reported with retatrutide — occurred in 4.8% and 6.5% of the 9 mg and 12 mg groups versus 2.7% on Ozempic. Discontinuation because of adverse events was 4.8% (9 mg), 7.9% (12 mg), and 2.7% (Ozempic).
Who Is Affected
Researchers now have the first randomized head-to-head efficacy benchmark for a triple agonist against a pure GLP-1 receptor agonist. Patients and clinicians get a preview of a likely filing — Lilly says it intends to file early next year — though retatrutide remains unapproved. Compounding suppliers and grey-market sellers face renewed attention, since demand for an unapproved drug typically precedes legal supply.
Timeline
- October 2026: TRANSCEND-T2D-2 topline announced; six Phase 3 readouts now complete for retatrutide.
- Early 2027: Lilly's stated filing target.
- Ongoing: TRIUMPH-5, a head-to-head Phase 3 versus tirzepatide in obesity.
- Later: Full data presented at a medical meeting and published in a peer-reviewed journal — when independent scrutiny begins.
What This Means for Researchers
The headline number is not the story; the safety profile is. A 12-point advantage in percentage weight loss comes bundled with double the discontinuation rate at the high dose and a dysesthesia signal that remains poorly characterized. Anyone modeling real-world persistence should treat 7.9% as a floor, since open-label trials tend to understate dropout.
Cardiac and hepatic outcome trials now running will determine whether the risk-benefit math holds outside a metabolically healthy population.
How to Verify Your Peptides
Research material circulating before approval carries no guarantee of identity or purity. Independent analysis is the only way to know what is in a vial:
- How peptide testing works
- HPLC versus LC-MS: what each method detects
- Identity, purity, and fill weight explained
- Retatrutide testing guide
Safe Alternatives
Retatrutide is investigational. Approved incretin therapies exist, and any decision about them belongs with a licensed clinician:
- Retatrutide compound profile
- Tirzepatide compound profile
- Semaglutide compound profile
- Vendor directory
Sources
- Regulatory announcements and company disclosures, October 28, 2026
- Industry reports on the TRANSCEND Phase 3 program
Retatrutide is an investigational compound. Nothing here is medical advice or dosing guidance.